{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=7", "query": { "intervention": "pembrolizumab", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 1844, "total_pages": 185, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T01:21:41.315Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05611229", "title": "Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Dabrafenib+Trametinib", "type": "COMBINATION_PRODUCT" }, { "name": "Ipilimumab+Nivolumab", "type": "COMBINATION_PRODUCT" }, { "name": "Vemurafenib+Cobimetinib", "type": "COMBINATION_PRODUCT" }, { "name": "Encorafenib+Binimetinib", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1975, "start_date": "2020-06-16", "completion_date": "2021-12-03", "has_results": false, "last_update_posted_date": "2023-04-06", "last_synced_at": "2026-10-25T01:21:41.315Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05611229" }, { "nct_id": "NCT05383170", "title": "A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Breast Cancer", "Advanced Melanoma" ], "interventions": [ { "name": "CyPep-1", "type": "DRUG" }, { "name": "Pembrolizumab 25 MG/ML [KEYTRUDA®]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cytovation AS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-03-21", "completion_date": "2024-09-23", "has_results": true, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-10-25T01:21:41.315Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Duarte, California • Detroit, Michigan + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05383170" }, { "nct_id": "NCT04879329", "title": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "disitamab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 372, "start_date": "2022-05-03", "completion_date": "2029-04-14", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-25T01:21:41.315Z", "location_count": 158, "location_summary": "Gilbert, Arizona • Anaheim, California • Arcadia, California + 96 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Arcadia", "state": "California" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879329" }, { "nct_id": "NCT05956041", "title": "Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous T Cell Lymphoma", "Fungoides Mycosis Sezary Syndrome" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Mogamulizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2023-12-06", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-25T01:21:41.315Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05956041" }, { "nct_id": "NCT02501096", "title": "A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 357, "start_date": "2015-07-22", "completion_date": "2022-07-11", "has_results": true, "last_update_posted_date": "2023-07-20", "last_synced_at": "2026-10-25T01:21:41.315Z", "location_count": 50, "location_summary": "Anchorage, Alaska • Oro Valley, Arizona • Tucson, Arizona + 34 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Oro Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02501096" }, { "nct_id": "NCT03664024", "title": "Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2018-10-30", "completion_date": "2021-11-05", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-10-25T01:21:41.315Z", "location_count": 3, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03664024" }, { "nct_id": "NCT03371979", "title": "Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small-cell Lung Cancer" ], "interventions": [ { "name": "Pegzilarginase", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aeglea Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2017-12-21", "completion_date": "2021-01-01", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-25T01:21:41.315Z", "location_count": 21, "location_summary": "Mobile, Alabama • Aurora, Colorado • Denver, Colorado + 18 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orange City", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03371979" }, { "nct_id": "NCT03530397", "title": "A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Selected Advanced Solid Tumors" ], "interventions": [ { "name": "MEDI5752", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel or Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 400, "start_date": "2018-04-24", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-25T01:21:41.315Z", "location_count": 7, "location_summary": "Detroit, Michigan • New York, New York • Chapel Hill, North Carolina + 4 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Chattanooga", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03530397" }, { "nct_id": "NCT03910660", "title": "A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Neuroendocrine Tumors", "Small Cell Carcinoma" ], "interventions": [ { "name": "BXCL701 plus Pembrolizumab", "type": "DRUG" }, { "name": "BXCL701 monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioXcel Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 98, "start_date": "2019-02-12", "completion_date": "2025-08-31", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-25T01:21:41.315Z", "location_count": 9, "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03910660" }, { "nct_id": "NCT07198074", "title": "Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Endometrial Carcinoma", "Recurrent Endometrial Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 255, "start_date": "2026-01-27", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-25T01:21:41.315Z", "location_count": 304, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 227 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07198074" } ] }